ATE370226T1 - Maus brustkrebs zelllinien die estrogen und progesteron rezeptoren exprimieren - Google Patents
Maus brustkrebs zelllinien die estrogen und progesteron rezeptoren exprimierenInfo
- Publication number
- ATE370226T1 ATE370226T1 AT01305230T AT01305230T ATE370226T1 AT E370226 T1 ATE370226 T1 AT E370226T1 AT 01305230 T AT01305230 T AT 01305230T AT 01305230 T AT01305230 T AT 01305230T AT E370226 T1 ATE370226 T1 AT E370226T1
- Authority
- AT
- Austria
- Prior art keywords
- cell lines
- progesterone receptors
- breast cancer
- cancer cell
- express estrogen
- Prior art date
Links
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 102000003998 progesterone receptors Human genes 0.000 title abstract 2
- 108090000468 progesterone receptors Proteins 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000008274 breast adenocarcinoma Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/613,707 US6808924B1 (en) | 2000-07-11 | 2000-07-11 | Mouse mammary tumor lines expressing estrogen and progesterone receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370226T1 true ATE370226T1 (de) | 2007-09-15 |
Family
ID=24458394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01305230T ATE370226T1 (de) | 2000-07-11 | 2001-06-15 | Maus brustkrebs zelllinien die estrogen und progesteron rezeptoren exprimieren |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6808924B1 (de) |
| EP (1) | EP1172435B1 (de) |
| AT (1) | ATE370226T1 (de) |
| DE (1) | DE60129892T2 (de) |
| ES (1) | ES2293967T3 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114686435B (zh) * | 2022-04-25 | 2023-03-28 | 中山大学孙逸仙纪念医院 | 一种雌激素受体阳性的小鼠乳腺癌细胞株的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2428792A1 (de) | 1974-06-14 | 1976-01-02 | Knoll Ag | Neue antiarrhythmika |
| DE3112055A1 (de) | 1981-03-27 | 1982-10-07 | Basf Ag, 6700 Ludwigshafen | Bispidinderivate, ihre herstellung und diese enthaltende arzneimittel |
| DE3234697A1 (de) | 1982-09-18 | 1984-03-22 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Neue diazabicyclo-(3,3,1)-nonane |
| PT88381B (pt) | 1987-09-09 | 1995-07-06 | Kali Chemie Pharma Gmbh | Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos |
| ATA237287A (de) | 1987-09-21 | 1993-02-15 | Vaillant Gmbh | Steuerung der temperatur des heizmediums einer umlaufheizung |
| DE3732094A1 (de) | 1987-09-24 | 1989-04-06 | Basf Ag | Bispidinderivate als klasse iii-antiarrhythmika |
| US5110933A (en) | 1989-11-13 | 1992-05-05 | Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
| US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
| DE4402931A1 (de) | 1994-02-01 | 1995-08-03 | Kali Chemie Pharma Gmbh | Neue 3-Phenylsulfonyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel |
| JP2000500454A (ja) | 1995-11-13 | 2000-01-18 | スミスクライン・ビーチャム・コーポレイション | 血液調節化合物 |
| SE9704709D0 (sv) | 1997-12-17 | 1997-12-17 | Astra Ab | Pharmaceutically active compounds |
| HUP0202214A3 (en) | 1999-04-09 | 2002-12-28 | Astrazeneca Ab | Adamantane derivatives, preparation and use thereof |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
-
2000
- 2000-07-11 US US09/613,707 patent/US6808924B1/en not_active Expired - Lifetime
-
2001
- 2001-06-15 AT AT01305230T patent/ATE370226T1/de not_active IP Right Cessation
- 2001-06-15 ES ES01305230T patent/ES2293967T3/es not_active Expired - Lifetime
- 2001-06-15 DE DE60129892T patent/DE60129892T2/de not_active Expired - Lifetime
- 2001-06-15 EP EP01305230A patent/EP1172435B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1172435B1 (de) | 2007-08-15 |
| EP1172435A1 (de) | 2002-01-16 |
| DE60129892D1 (de) | 2007-09-27 |
| DE60129892T2 (de) | 2008-04-30 |
| US6808924B1 (en) | 2004-10-26 |
| ES2293967T3 (es) | 2008-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116970T1 (el) | Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης | |
| PL2444085T3 (pl) | Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka | |
| EA202191958A1 (ru) | Способы и соединения | |
| MX2010005966A (es) | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). | |
| WO2004058171A3 (en) | Antibodies against gpr64 and uses thereof | |
| EP2010911A4 (de) | Behandlung von egf-rezeptormutanten exprimierenden tumoren | |
| BR112012016253A2 (pt) | "método para levantamento geofísico tendo pelo menos uma fonte e um receptor, conjunto de dados de levantamento geofísico adquirido indicativo". | |
| CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| ATE369425T1 (de) | Antikörper gegen eine lar-phosphatase untereinheit | |
| CL2020000977A1 (es) | Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos. | |
| BRPI0419348B8 (pt) | métodos para produzir o conjugado de maitansinóide-agente de ligação celular | |
| MX2024005712A (es) | Moleculas de anticuerpo y conjugados. | |
| AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
| SV2003001102A (es) | Ligandos del receptor de 5-ht y sus usos ref. pc11892 | |
| DE602005025805D1 (de) | Stabilisierte polymer-thiol-reagenzien | |
| ATE521366T1 (de) | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| MX2010007357A (es) | Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular. | |
| GR20070100553A (el) | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης | |
| DE60018215D1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| MX2010001955A (es) | Enlazadores polimericos que contienen porciones de disulfuro-piridilo. | |
| NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
| WO2006002895A3 (en) | Conjugates of antibody and duoarmycin derivatives as antitumor agents | |
| WO2011137245A3 (en) | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |